Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhHGF in Fulminant and Late-Onset Hepatic Failure
NCT00225901Phase 2Unknown
- Sponsor
- Kyoto University
- Start
- Sep 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of olamepermin alfa in acute liver failure (ALF), hepatic failure, sponsored by Kyoto University. Status: unknown.
02
Drugs
olamepermin alfa
03
Conditions
acute liver failure (ALF)hepatic failure
Beyond the preview
Go deeper on NCT00225901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00225901.